-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66

Benzinga·11/05/2026 16:07:33
Listen to the news
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.